Industry: Biotechnology Region: Croatia Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
This is a Croatian biotechnology company, which is in a leading position in glycan research and precision medicine. The company has analyzed more than 150,000 individual sugar groups, and the current analysis speed is about 30,000 times a year. GlycanAge UK was established as a commercial spin-off of Genos in 2016, aiming at accelerating the transition from reactive health to active health through glycan biomarkers. Polysaccharide has changed more than ten years before CVD, hypertension, insulin resistance and menopause. It is a dark horse in the longevity competition and the key to unlock this trillion-dollar industry. GlycanAge packaged the solution for measuring biological aging into a simple blood test to take home.
The company and GlycanAge UK have contributed to women's health through scientific research on MenoAge, a personalized health monitoring blood test for perimenopausal women. MenoAge is unique in its glycan technology developed in the company's laboratory. IgG glycan can integrate the influence of sex hormone fluctuation within a few weeks, which may make it a HbA1c-type biomarker of early signs of health deterioration related to perimenopausal period.
At present, the company has developed a MenoAge test and sugar spectrum analysis service based on glycan technology, which is used for early perimenopausal detection and the effectiveness of hormone replacement therapy. My research aims at scientifically preventing the long-term adverse health consequences of perimenopausal period, promoting healthy aging and health, and prolonging women's healthy life and longevity. Looking for business partners.